Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

China Medical System Licenses Teikoku’s Lidoderm for Postherpetic Neuralgia in China

Fineline Cube Feb 13, 2026
Company Deals

Salubris Pharma Files Hong Kong IPO for Secondary Listing to Expand Cardiorenal Metabolic Franchise

Fineline Cube Feb 13, 2026
Company Deals

Immunofoco Bio Files Hong Kong IPO for Solid Tumor CAR-T Pipeline

Fineline Cube Feb 13, 2026
Company Deals

Ribo Life Science Licenses $4.4 Billion MASH siRNA Portfolio to Madrigal Pharmaceuticals

Fineline Cube Feb 12, 2026
Company Deals

Novartis Secures Long-Term Actinium-225 Supply from Niowave for Radioligand Therapy Expansion

Fineline Cube Feb 12, 2026
Policy / Regulatory

FDA Cracks Down on Compounded GLP-1 APIs; Novo Nordisk Sues Hims & Hers for Patent Infringement

Fineline Cube Feb 11, 2026
Company Drug

Amgen’s UPLIZNA Wins European Approval for Generalized Myasthenia Gravis

Fineline Cube Feb 13, 2026
Company Drug

Innovent Biologics Initiates Phase 3 HeriCare-Breast01 Study for IBI354 in HER2+ Breast Cancer

Fineline Cube Feb 13, 2026
Company Deals

Shanghai Pharmaceuticals’ RMB 4.66 Billion M&A Fund Completes AMAC Registration

Fineline Cube Apr 17, 2025

China’s Shanghai Pharmaceuticals Holding Ltd (SPH, HKG: 2607, SHA: 601607) has announced the completion of...

Company Deals

Zhaoke Ophthalmology Signs Distribution Agreements with Thailand’s Interpharma for Myopia and Presbyopia Treatments

Fineline Cube Apr 17, 2025

China-based Zhaoke Ophthalmology Ltd (HKG: 6622) has announced the signing of three distribution and supply...

Company Drug

Eisai and Biogen Win EU Approval for Leqembi in Early Alzheimer’s Disease

Fineline Cube Apr 17, 2025

Eisai Co., Ltd. (TYO: 4523) and Biogen Inc. (NASDAQ: BIIB) jointly announced that they have...

Company

Jiangsu Wuzhong Pharma Faces Forced Delisting After CSRC Investigation

Fineline Cube Apr 17, 2025

China-based Jiangsu Wuzhong Pharmaceutical Group Corp. (SHA: 600200) has disclosed a potential forced delisting from...

Company Drug

Sichuan Biokin’s BL-M09D1 ADC Receives NMPA Clinical Trial Clearance for Solid Tumors

Fineline Cube Apr 17, 2025

Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has announced that its antibody-drug conjugate (ADC) BL-M09D1...

Company Deals

Da Ren Tang Sells Stake in Tianjin Shike to Haleon for RMB 1.623 Billion

Fineline Cube Apr 17, 2025

Tianjin Pharmaceutical Da Ren Tang Group Co., Ltd. (SHA: 600329), a traditional Chinese medicine (TCM)...

Company Deals Drug

Akeso Biopharma Partners with Virogin to Test Ivonescimab and VG201 in Colorectal Cancer Trial

Fineline Cube Apr 17, 2025

China-based Akeso Biopharma (HKG: 9926) has entered into a clinical collaboration with Virogin Biotech Co.,...

Company Deals

Berry Genomics Collaborates with Beijing Children’s Hospital on Newborn Birth Defects Screening Project

Fineline Cube Apr 17, 2025

China-based genomics testing company Berry Genomics (SHE: 000710) has entered into a project achievement translation...

Policy / Regulatory

Trump Orders HHS to Reduce Drug Prices, Revamp Medicare Negotiation Program

Fineline Cube Apr 17, 2025

President Donald Trump issued a new Executive Order aimed at reducing drug prices for American...

Company Drug

Galderma Launches Sculptra in China as First Regenerative Biostimulator

Fineline Cube Apr 16, 2025

Switzerland-based skin care specialist Galderma officially launched Sculptra in China this week, marking the first...

Company Drug

Easton Pharma’s EP-9001A Shows Promising Results in Phase Ib for Bone Metastasis Cancer Pain

Fineline Cube Apr 16, 2025

Chengdu-based Easton Pharmaceutical Co., Ltd (SHA: 688513) has announced preliminary statistical analysis results from the...

Company Medical Device

Edwards Lifesciences Gains EU CE Mark for SAPIEN M3 Mitral Valve System

Fineline Cube Apr 16, 2025

US medical device giant Edwards Lifesciences Corporation (NYSE: EW) has announced that it has received...

Company Drug

InnoCare Pharma’s Zurletrectinib NDA Accepted by China’s CDE for TRK Fusion Cancers

Fineline Cube Apr 16, 2025

Beijing-based biopharmaceutical company InnoCare Pharma (HKG: 9969, SHA: 688428) has announced that China’s Center for...

Policy / Regulatory

NHC Releases Standardized Family Doctor Service Packages for Key Demographic Groups

Fineline Cube Apr 16, 2025

The National Health Commission (NHC) has issued the “List of Basic Service Packages for Family...

Company Deals Medical Device

Kosell Medtech Partners with Wenzhou Medical University on K-Sheath System

Fineline Cube Apr 16, 2025

China-based Kossel Medtech (Suzhou) Co., Ltd., a vascular interventional medical device platform company, has entered...

Company Drug

Sichuan Biokin Secures Four Phase II Approvals for BL-B01D1 in Combination Therapies

Fineline Cube Apr 16, 2025

China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has announced that it has secured four...

Company Drug

Hansoh Pharmaceutical Gains Clinical Approval for KRAS G12D Targeted Drug HS-10529

Fineline Cube Apr 16, 2025

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced that it has received clinical...

Company Drug

AccurEdit Therapeutics Reports Positive 24-Week Data for ART002 in HeFH Patients

Fineline Cube Apr 16, 2025

Suzhou-based gene editing specialist AccurEdit Therapeutics has announced the completion of a 24-week follow-up for...

Company Deals

Cyprumed Signs Non-Exclusive License Agreement with MSD for Oral Peptide Delivery Tech

Fineline Cube Apr 16, 2025

Germany-based Cyprumed GmbH has entered into a non-exclusive license and option agreement with Merck, Sharp...

Company Drug Policy / Regulatory

US Commerce Department Launches Section 232 Probe on Pharma Imports and National Security

Fineline Cube Apr 16, 2025

The US Department of Commerce (DoC) has initiated a Section 232 investigation to evaluate the...

Posts pagination

1 … 135 136 137 … 624

Recent updates

  • China Medical System Licenses Teikoku’s Lidoderm for Postherpetic Neuralgia in China
  • Organon Reports 2025 Revenue Decline to $6.2 Billion; JADA Sale and Portfolio Pressures Weigh
  • Salubris Pharma Files Hong Kong IPO for Secondary Listing to Expand Cardiorenal Metabolic Franchise
  • Sanofi Appoints Belén Garijo as New CEO to Drive R&D Innovation and Productivity
  • Immunofoco Bio Files Hong Kong IPO for Solid Tumor CAR-T Pipeline
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

China Medical System Licenses Teikoku’s Lidoderm for Postherpetic Neuralgia in China

Company

Organon Reports 2025 Revenue Decline to $6.2 Billion; JADA Sale and Portfolio Pressures Weigh

Company Deals

Salubris Pharma Files Hong Kong IPO for Secondary Listing to Expand Cardiorenal Metabolic Franchise

Company

Sanofi Appoints Belén Garijo as New CEO to Drive R&D Innovation and Productivity

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.